Last reviewed · How we verify
VOQUEZNA® Triple Pak®
VOQUEZNA® Triple Pak® is a Potassium-competitive acid blocker (PCAB) combination therapy Small molecule drug developed by University of Miami. It is currently FDA-approved for Helicobacter pylori eradication in adults.
VOQUEZNA Triple Pak is a combination therapy containing vonoprazan (a potassium-competitive acid blocker) plus amoxicillin and clarithromycin that eradicates Helicobacter pylori by suppressing gastric acid and delivering dual antibiotics.
VOQUEZNA Triple Pak is a small molecule treatment used for Helicobacter Pylori Infection, Helicobacter Pylori Gastritis, and Gastric Cancer, as indicated by ClinicalTrials.gov.
At a glance
| Generic name | VOQUEZNA® Triple Pak® |
|---|---|
| Sponsor | University of Miami |
| Drug class | Potassium-competitive acid blocker (PCAB) combination therapy |
| Target | H+ K+-ATPase (vonoprazan component); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vonoprazan is a potassium-competitive acid blocker (PCAB) that provides rapid and sustained gastric acid suppression, creating an optimal environment for the antibiotics amoxicillin and clarithromycin to eliminate H. pylori infection. This triple combination approach targets the bacterium through both acid reduction and direct antimicrobial activity, improving eradication rates compared to traditional proton pump inhibitor-based regimens.
Approved indications
- Helicobacter pylori eradication in adults
Common side effects
- Diarrhea
- Taste perversion
- Nausea
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VOQUEZNA® Triple Pak® CI brief — competitive landscape report
- VOQUEZNA® Triple Pak® updates RSS · CI watch RSS
- University of Miami portfolio CI
Frequently asked questions about VOQUEZNA® Triple Pak®
What is VOQUEZNA® Triple Pak®?
How does VOQUEZNA® Triple Pak® work?
What is VOQUEZNA® Triple Pak® used for?
Who makes VOQUEZNA® Triple Pak®?
What drug class is VOQUEZNA® Triple Pak® in?
What development phase is VOQUEZNA® Triple Pak® in?
What are the side effects of VOQUEZNA® Triple Pak®?
What does VOQUEZNA® Triple Pak® target?
Related
- Drug class: All Potassium-competitive acid blocker (PCAB) combination therapy drugs
- Target: All drugs targeting H+ K+-ATPase (vonoprazan component); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin)
- Manufacturer: University of Miami — full pipeline
- Therapeutic area: All drugs in Gastroenterology / Infectious Disease
- Indication: Drugs for Helicobacter pylori eradication in adults
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing